Anzeige
Meldung des Tages: 20-Milliarden-Markt vor dem Durchbruch: Dieser Drohnen-Player baut ein komplettes Luftfahrt-Ökosystem auf

Travere Therapeutics News

Aktie
WKN:  A2QHYP ISIN:  US89422G1076 US-Symbol:  TVTX Branche:  Biotechnologie Land:  USA
28,84 $
+1,595 $
+5,85%
24,829 € 20:47:02 Uhr
Depot/Watchlist
Marktkapitalisierung *
3,00 Mrd. €
Streubesitz
-
KGV
-4,50
Index-Zuordnung
-

Travere Therapeutics News

28.01.26 - PR Newswire
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to ...
26.09.25 - PR Newswire
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy PR Newswire
02.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
07.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
01.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire

Newssuche

Videos

newspaper
04.03.26 -3,16%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »